Search

Displaying results 7611 - 7620 of 10000 in total
  1. Drug

    Lerociclib

    go.drugbank.com/drugs/DB16218
    Investigational

    Lerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast

  2. Drug

    Lunasine

    go.drugbank.com/drugs/DB16223
    Investigational

    Lunasine is under investigation in clinical trial NCT02709330 (ALS Reversals - Lunasin Regimen).

  3. Drug

    Mavelertinib

    go.drugbank.com/drugs/DB16228
    Investigational

    Mavelertinib is under investigation in clinical trial NCT02349633 (Study for Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)).

  4. Drug

    Mesdopetam

    go.drugbank.com/drugs/DB16229
    Investigational

    Mesdopetam is under investigation in clinical trial NCT04435431 (A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia).

  5. Drug

    Milciclib Maleate

    go.drugbank.com/drugs/DB16232
    Investigational

    Milciclib Maleate is under investigation in clinical trial NCT01301391 (Study of Oral PHA-848125AC in Patients With Malignant Thymoma Previously Treated With Multiple Lines of Chemotherapy).

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  6. Drug

    Miricorilant

    go.drugbank.com/drugs/DB16234
    Investigational

    Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  7. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: Pkr-in-1
  8. Drug

    Molibresib

    go.drugbank.com/drugs/DB16239
    Investigational

    Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects

    Categories: Heterocyclic Compounds, 2-Ring
  9. Drug

    TBA-7371

    go.drugbank.com/drugs/DB16243
    Investigational

    TBA-7371 is under investigation in clinical trial NCT04176250 (Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis).

  10. Drug

    Nanoparticle Epirubicin

    go.drugbank.com/drugs/DB16248
    Investigational

    It is a novel [epirubicin] drug-conjugated polymeric micelle. … Nanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma).